FY2024 EPS Estimates for Inovalis Real Estate Investment Trust Decreased by Analyst (TSE:INO)

Posted by on Aug 20th, 2024

Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Desjardins cut their FY2024 earnings per share (EPS) estimates for Inovalis Real Estate Investment Trust in a report issued on Wednesday, August 14th. Desjardins analyst A. Leon now expects that the company will post earnings per share of $0.06 for the year, down from their prior estimate of $0.07. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s FY2025 earnings at $0.05 EPS.

Inovalis Real Estate Investment Trust Stock Performance

Inovalis Real Estate Investment Trust Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Further Reading

Earnings History and Estimates for Inovalis Real Estate Investment Trust (TSE:INO)

Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.